3. Maidhof R, Alipui DO, Rafiuddin A, et al. Emerging trends in biological therapy for intervertebral disc degeneration. Discov Med, 2012, 14(79):401-411.
[2]
4. Saucedo JM, Yaffe MA, Berschback JC, et al. Platelet-rich plasma. J Hand Surg Am, 2012, 37(3):587-589.
[3]
7. Kepler CK, Ponnappan RK, Tannoury CA, et al. The molecular basis of intervertebral disc degeneration. Spine J, 2013, 13(3):318-330.
[4]
8. Kim KW, Chung HN, Ha KY, et al. Senescence mechanisms of nucleus pulposus chondrocytes in human intervertebral discs. Spine J, 2009, 9(8):658-666.
[5]
9. Le Maitre CL, Freemont AJ, Hoyland JA. Accelerated cellular senescence in degenerative intervertebral discs:a possible role in the pathogenesis of intervertebral disc degeneration. Arthritis Res Ther, 2007, 9(3):R45.
[6]
10. Duance VC, Crean JK, Sims TJ, et al. Changes in collagen crosslinking in degenerative disc disease and scoliosis. Spine, 1998, 23(23):2545-2551.
[7]
14. Gruber HE, Ingram JA, Hanley EN Jr. Immunolocalization of MMP-19 in the human intervertebral disc:implications for disc aging and degeneration. Biotech Histochem, 2005, 80(3-4):157-162.
[8]
20. Cui LY, Liu SL, Ding Y, et al. IL-1beta sensitizes rat intervertebral disc cells to fas ligand mediated apoptosis in vitro. Acta Pharmacol Sin, 2007, 28(10):1671-1676.
[9]
22. Igarashi T, Kikuchi S, Shubayev V, et al. 2000 Volvo Award winner in basic science studies:Exogenous tumor necrosis factor-alpha mimics nucleus pulposus-induced neuropathology. Molecular, histologic, and behavioral comparisons in rats. Spine, 2000, 25(23):2975-2980.
[10]
23. Lee S, Moon CS, Sul D, et al. Comparison of growth factor and cytokine expression in patients with degenerated disc disease and herniated nucleus pulposus. Clin Biochem, 2009, 42(15):1504-1511.
[11]
24. Hengartner MO. The biochemistry of apoptosis. Nature, 2000, 407(6805):770-776.
[12]
26. Johnson WE, Caterson B, Eisenstein SM, et al. Human intervertebral disc aggrecan inhibits nerve growth in vitro. Arthritis Rheum, 2002, 46(10):2658-2664.
[13]
30. Alsousou J, Thompson M, Hulley P, et al. The biology of plateletrich plasma and its application in trauma and orthopaedic surgery:A review of the literature. J Bone Joint Surg Br, 2009, 91(8):987-996.
[14]
43. Fujita N, Imai J, Suzuki T, et al. Vascular endothelial growth factor-A is a survival factor for nucleus pulposus cells in the intervertebral disc. Biochem Biophys Res Commun, 2008, 372(2):367-372.
[15]
44. Liu Y, Kong J, Chen BH, et al. Combined expression of CTGF and tissue inhibitor of metalloprotease-1 promotes synthesis of proteoglycan and collagen type Ⅱ in rhesus monkey lumbar intervertebral disc cells in vitro. Chin Med J (Engl), 2010, 123(15):2082-2087.
31. Gentile P, Cervelli V. Autologous platelet-rich plasma:Guidelines in plastic surgery. Plast Reconstr Surg, 2010, 126(5):269e-270e.
[19]
35. Wang HL, Avila G. Platelet rich plasma:myth or reality? Eur J Dent, 2007, 1(4):192-194.
[20]
39. Gruber HE, Fisher EC Jr, Desai B, et al. Human intervertebral disc cells from the annulus:three-dimensional culture in agarose or alginate and responsiveness to TGF-beta1. Exp Cell Res, 1997, 235(1):13-21.
[21]
47. Chen WH, Lo WC, Lee JJ, et al. Tissue-engineered intervertebral disc and chondrogenesis using human nucleus pulposus regulated through TGF-beta1 in plateletrich plasma. J Cell Physiol, 2006, 209(3):744-754.
54. Chen WH, Liu HY, Lo WC, et al. Intervertebral disc regeneration in an ex vivo culture system using mesenchymal stem cells and plateletrich plasma. Biomaterials, 2009, 30(29):5523-5533.
[24]
56. Mietsch A, Neidlinger-Wilke C, Schrezenmeier H, et al. Evaluation of platelet-rich plasma and hydrostatic pressure regarding cell differentiation in nucleus pulposus tissue engineering. J Tissue Eng Regen Med, 2013, 7(3):244-252.
[25]
1. Hughes SP, Freemont AJ, Hukins DW, et al. The pathogenesis of degeneration of the intervertebral disc and emerging therapies in the management of back pain. J Bone Joint Surg (Br), 2012, 94(10):1298-1304.
[26]
5. Alsousou J, Ali A, Willett K, et al. The role of platelet-rich plasma in tissue regeneration. Platelets, 2013, 24(3):173-182.
[27]
17. Le Maitre CL, Freemont AJ, Hoyland JA. Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc. J Pathol, 2004, 204(1):47-54.
[28]
18. Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res Ther, 2005, 7(4):R732-745.
[29]
19. Jimbo K, Park JS, Yokosuka K, et al. Positive feedback loop of interleukin-1beta upregulating production of inflammatory mediators in human intervertebral disc cells in vitro. J Neurosurg Spine, 2005, 2(5):589-595.
[30]
25. Freemont AJ, Peacock TE, Goupille P, et al. Nerve ingrowth into diseased intervertebral disc in chronic back pain. Lancet, 1997, 350(9072):178-181.
[31]
28. Freemont AJ, Watkins A, Le Maitre C, et al. Nerve growth factor expression and innervation of the painful intervertebral disc. J Pathol, 2002, 197(3):286-292.
[32]
2. Kepler CK, Anderson DG, Tannoury C, et al. Intervertebral disk degeneration and emerging biologic treatments. J Am Acad Orthop Surg, 2011, 19(9):543-553.
[33]
6. Podd D. Platelet-rich plasma therapy:origins and applications investigated. JAAPA, 2012, 25(6):44-49.
[34]
11. Cs-Szabo G, Ragasa-San Juan D, Turumella V, et al. Changes in mRNA and protein levels of proteoglycans of the anulus fibrosus and nucleus pulposus during intervertebral disc degeneration. Spine, 2002, 27(20):2212-2219.
[35]
12. Weiler C, Nerlich AG, Zipperer J, et al. 2002 SSE award competition in basic science:expression of major matrix metalloproteinases is associated with intervertebral disc degradation and resorption. Eur Spine J, 2002, 11(4):308-320.
[36]
13. Roberts S, Caterson B, Menage J, et al. Matrix metalloproteinases and aggrecanase:their role in disorders of the human intervertebral disc. Spine, 2000, 25(23):3005-3013.
[37]
15. Pockert AJ, Richardson SM, Le Maitre CL, et al. Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases.
[38]
16. during human intervertebral disc degeneration. Arthritis Rheum, 2009, 60(2):482-491.
[39]
21. Freemont AJ. The cellular pathobiology of the degenerate intervertebral disc and discogenic back pain. Rheumatology (Oxford), 2009, 48(1):5-10.
[40]
27. Johnson WE, Caterson B, Eisenstein SM, et al. Human intervertebral disc aggrecan inhibits endothelial cell adhesion and cell migration in vitro. Spine, 2005, 30(10):1139-1147.
[41]
29. Gruber HE, Ingram JA, Hoelscher G, et al. Brain-derived neurotrophic factor and its receptor in the human and the sand rat intervertebral disc. Arthritis Res Ther, 2008, 10(4):R82.
33. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma:implications for wound healing. Plast Reconstr Surg, 2004, 114(6):1502-1508.
[44]
34. Kon E, Buda R, Filardo G, et al. Platelet-rich plasma:intra-articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc, 2010, 18(4):472-479.
[45]
36. Mishra A, Woodhall J Jr, Vieira A. Treatment of tendon and muscle using platelet-rich plasma. Clin Sports Med, 2009, 28(1):113-125.
[46]
37. Thompson JP, Oegema TR Jr, Bradford DS. Stimulation of mature canine intervertebral disc by growth factors. Spine, 1991, 16(3):253-260.
[47]
38. Osada R, Ohshima H, Ishihara H, et al. Autocrine/paracrine mechanism of insulin-like growth factor-1 secretion, and the effect of insulin-like growth factor-1 on proteoglycan synthesis in bovine intervertebral discs. J Orthop Res, 1996, 14(5):690-699.
[48]
40. Gruber HE, Norton HJ, Hanley EN Jr. Anti-apoptotic effects of IGF- 1 and PDGF on human intervertebral disc cells in vitro. Spine, 2000, 25(17):2153-2157.
[49]
41. Pratsinis H, Kletsas D. PDGF, bFGF and IGF-I stimulate the proliferation of intervertebral disc cells in vitro via the activation of the ERK and Akt signaling pathways. Eur Spine J, 2007, 16(11):1858-1866.
[50]
42. Hayes AJ, Ralphs JR. The response of foetal annulus fibrosus cells to growth factors:modulation of matrix synthesis by TGF-β1 and IGF-1. Histochem Cell Biol, 2011, 136(2):163-175.
[51]
45. Wang SZ, Rui YF, Tan Q, et al. Enhancing intervertebral disc repair and regeneration through biology:platelet-rich plasma as an alternative strategy. Arthritis Res Ther, 2013, 15(5):220.
[52]
46. Akeda K, An HS, Pichika R, et al. Platelet-rich plasma (PRP) stimulates the extracellular matrix metabolism of porcine nucleus pulposus and anulus fibrosus cells cultured in alginate beads. Spine, 2006, 31(9):959-966.
[53]
48. Nagae M, Ikeda T, Mikami Y, et al. Intervertebral disc regeneration using platelet-rich plasma and biodegradable gelatin hydrogel microspheres. Tissue Eng, 2007, 13(1):147-158.
[54]
49. Sawamura K, Ikeda T, Nagae M, et al. Characterization of in vivo effects of platelet-rich plasma and biodegradable gelatin hydrogel microspheres on degenerated intervertebral discs. Tissue Eng, 2009, 15(12):3719-3727.
[55]
50. Gullung GB, Woodall JW, Tucci MA, et al. Platelet-rich plasma effects on degenerative disc disease:analysis of histology and imaging in an animal model. Evid Based Spine Care J, 2011, 2(4):13-18.
[56]
51. Obata S, Akeda K, Imanishi T, et al. Effect of autologous plateletrich plasma-releasate on intervertebral disc degeneration in the rabbit anular puncture model:a preclinical study. Arthritis Res Ther, 2012, 14(6):R241.
[57]
53. Kim HJ, Yeom JS, Koh YG, et al. Anti-inflammatory effect of platelet-rich plasma on nucleus pulposus cells with response of TNF-α and IL-1. J Orthop Res, 2014, 32(4):551-556.
